Tim Pickett's departure as Chief Medical Officer of Nakamoto Inc. was reported, effective August 3, 2026; the filing names no successor. As of November 6, 2026, Nakamoto Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 22, 2026 to August 4, 2026, naming 1 departure (Form 8-K, August 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Nakamoto Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Nakamoto Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-22 to 2026-08-04. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Nakamoto Inc. files it.
Also on the record for Nakamoto Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 1, 2026 | Stake report, Schedule 13D/A, by David Bailey | 18.25% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Alyeska Investment Group, L.P. | 3.71% of the class | 5%+ stakes | Source |
| February 27, 2026 | Stake report, Schedule 13D, by David Bailey | 17.33% of the class | 5%+ stakes | Source |
| February 26, 2026 | Stake report, Schedule 13G, by Bailey Calli Sullivan | 16% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Alyeska Investment Group, L.P. | 5.93% of the class | 5%+ stakes | Source |
| July 8, 2025 | Form D, private offering | $51.50M sold | Form D page | Source |
| June 26, 2025 | Form D, private offering | $711.69M sold | Form D page | Source |
Selling to them or working with them? See who runs Nakamoto Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Nakamoto Inc. and the records around it.
Nakamoto Inc. elsewhere on the record
- 5%+ stake filings Jun 2026
- Form D filing Jul 2025
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Alyeska Investment Group, L.P. also filed stake reports on 81 other companies: ABUNDIA GLOBAL IMPACT GROUP, INC. (Aug 2026), Bakkt, Inc. (Aug 2026), BATTALION OIL CORP (Aug 2026)
Watch Nakamoto Inc.
Get an email when Nakamoto Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nakamoto Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nakamoto Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nakamoto Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-04 | Out | Chief Medical Officer | 2026-08-03 | 8-K, 2026-08-04 | |
| 2026-05-22 | Reported | not named in the filing | 8-K, 2026-05-22 |
Who leads Nakamoto Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Tim Pickett, departure reported, effective 2026-08-03 (filed 2026-08-04). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Nakamoto Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Nakamoto Inc., with the record behind each one.
Find candidates like Chief Medical Officer at Nakamoto Inc.Every change, in the filing's words
Departing: Tim Pickett, Chief Medical Officer, effective 2026-08-03
On August 3, 2026, Tim Pickett resigned from all positions that he held with Nakamoto Inc., a Delaware corporation (the " Company "), and its affiliates, including as a director of the Company, Chief Medical Officer of the Company, and Chief Executive Officer of Kindly LLC, in each case effective August 3, 2026.
- Mr. Pickett's resignation was not a result of any disagreement with the Company on any matter relating to the Company's financial reporting, operations, policies or practices.
- The Company thanks Mr. Pickett for his service and contributions.
- On August 3, 2026, the Company and Mr. Pickett entered into a Separation Agreement and Release (the "Separation Agreement").
- Subject to Mr. Pickett's execution and non-revocation of the Separation Agreement, the Company agreed to pay Mr. Pickett a separation payment in the gross amount of $911,468.58, less applicable tax withholdings and other lawful deductions, payable in a single installment on or during the first scheduled Company pay cycle occurring after the date that is one week following the Separation Agreement Effective Date (as defined below).
- Except for the payments and benefits provided under the Separation Agreement, Mr. Pickett's compensation and benefits from the Company ceased as of his last day of employment.
- The Separation Agreement provides for, among other things, mutual releases of claims (subject to customary exceptions, including claims that may not be waived as a matter of law and each party's right to enforce the Separation Agreement), confidentiality obligations of Mr. Pickett, and reciprocal non-disparagement and cooperation obligations.
Reported
Mr. Evans has not entered into any material plan, contract, arrangement or amendment in connection with his appointment to the Board.
- On May 21, 2026, the board of directors (the "Board") of Nakamoto Inc., a Delaware corporation (the "Company") approved an increase in the number of directors constituting the Board from six (6) to seven (7) and appointed Tyler Evans, Chief Investment Officer of the Company, as a Class II director to serve until the Company's 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
- Mr. Evans will not serve on any committees of the Board.
- Mr. Evans does not qualify as an independent director for purposes of Nasdaq Stock Market LLC listing rules, as well as applicable rules of the United States Securities and Exchange Commission (the "SEC").
- Mr. Evans will not receive additional compensation in connection with his service on the Board and there will be no modification to Mr. Evans' existing compensation arrangement as Chief Investment Officer of the Company.
Tools for this story
Each opens in a new tab, filled in for Nakamoto Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.